{
    "clinical_study": {
        "@rank": "324",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04263402"
        },
        "id_info": {
            "org_study_id": "TJ20200201",
            "nct_id": "NCT04263402"
        },
        "brief_title": "The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia",
        "official_title": "An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tongji Hospital",
                "agency_class": "Other"
            }
        },
        "source": "Tongji Hospital",
        "oversight_info": {
            "has_dmc": "No",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "At present, there is no specific and effective antiviral therapy.In this study, an open,\n      prospective/retrospective, randomized controlled cohort study was designed to compare the\n      efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study\n      explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable\n      evidence-based basis for the treatment."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Actual",
            "#text": "February 1, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "July 1, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "June 1, 2020"
        },
        "phase": "Phase 4",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "Single (Participant)"
        },
        "primary_outcome": [
            {
                "measure": "Rate of disease remission",
                "time_frame": "day 7",
                "description": "For mild patients: disease remission refers to relieved symptoms with improved lung CT; For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2>93% or PaO2/FiO2 >300mmHg."
            },
            {
                "measure": "Rate and time of entering the critical stage",
                "time_frame": "day 7",
                "description": "the critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs ICU monitoring and treatment."
            }
        ],
        "secondary_outcome": [
            {
                "measure": "Rate of normal tempreture",
                "time_frame": "day 7",
                "description": "Rate of patients without fever at day 7"
            },
            {
                "measure": "Rate of respiratory symptom remission",
                "time_frame": "day 7",
                "description": "Rate of patients with respiratory symptom remission at day 7"
            },
            {
                "measure": "Rate of lung imaging recovery",
                "time_frame": "day 7",
                "description": "Rate of patients with lung imaging recovery at day 7"
            },
            {
                "measure": "Rate of laboratory indicator recovery",
                "time_frame": "day 7",
                "description": "Rate of patients with laboratory indicator recovery at day 7"
            },
            {
                "measure": "Rate of undetectable viral RNA",
                "time_frame": "day 7",
                "description": "Rate of patients withundetectable viral RNA at day 7"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "100"
        },
        "condition": "2019-nCoV Severe Pneumonia",
        "arm_group": [
            {
                "arm_group_label": "Methylprednisolone(<40mg/d)",
                "arm_group_type": "Experimental"
            },
            {
                "arm_group_label": "Methylprednisolone(40~80mg/d)",
                "arm_group_type": "Experimental"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Methylprednisolone",
                "description": "Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).",
                "arm_group_label": "Methylprednisolone(<40mg/d)"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Methylprednisolone",
                "description": "Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).",
                "arm_group_label": "Methylprednisolone(40~80mg/d)"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.Meet the definition of severe pneumonia(Comply with any of the followings):\n\n          1. Shortness of breath,RR\u226530 bpm;\n\n          2. In a resting state:SPO2\u226493%;\n\n          3. PaO2/FiO2\u2264300mmHg.\n\n        2.2019-nCoV nucleic acid test was positive.\n\n        3.CT of the lung conformed to the manifestation of viral pneumonia.\n\n        Exclusion Criteria:\n\n          1. dying state (i.e. survival time is less than 24 hours);\n\n          2. progressive malignant tumor with life expectancy less than 6 months;\n\n          3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs)\n\n          4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months\n             or short-term glucocorticoid therapy in the past 4 weeks;\n\n          5. pregnancy\n\n          6. patients with glucocorticoid taboos"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Qing Ning, Professor",
            "phone": "+8613971521450",
            "email": "qning@vip.sina.com"
        },
        "overall_contact_backup": {
            "last_name": "Meifang Han, Professor",
            "phone": "+8613986093605",
            "email": "mfhan@foxmail.com"
        },
        "location": {
            "facility": {
                "name": "Department and Institute of Infectious Disease",
                "address": {
                    "city": "Wuhan",
                    "state": "Hubei",
                    "zip": "430030",
                    "country": "China"
                }
            },
            "status": "Recruiting",
            "contact": {
                "last_name": "Qin Ning, professor",
                "email": "qning@vip.sina.com"
            },
            "contact_backup": {
                "last_name": "Meifang Han, professor",
                "email": "mfhan@foxmail.com"
            }
        },
        "location_countries": {
            "country": "China"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "February 2, 2020",
        "study_first_submitted_qc": "February 7, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "February 10, 2020"
        },
        "last_update_submitted": "March 14, 2020",
        "last_update_submitted_qc": "March 14, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "March 17, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Tongji Hospital",
            "investigator_full_name": "Qin Ning",
            "investigator_title": "Professor"
        },
        "condition_browse": {
            "mesh_term": "Pneumonia"
        },
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone",
                "Methylprednisolone Acetate",
                "Methylprednisolone Hemisuccinate",
                "Prednisolone",
                "Prednisolone acetate",
                "Hormones",
                "Prednisolone hemisuccinate",
                "Prednisolone phosphate"
            ]
        },
        "patient_data": {
            "sharing_ipd": "Undecided"
        }
    }
}